SequelSEC

Semnur Pharmaceuticals, Inc. SMNR

Pharmaceutical Preparations · CIK 0001913577 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$160.42M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Semnur Pharmaceuticals, Inc. (SMNR) reported net income of -$160.42M for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Semnur Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Semnur Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
RevenueUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$160.42M-$4.69M-$3.17MUnavailable
Net income-$160.42M-$4.69M$632.54K-$419.39K
Research & development$2.55M$1.71MUnavailableUnavailable
Weighted-average diluted sharesshares 204.78Mshares 200.00MUnavailableUnavailable
Pretax income$0$0UnavailableUnavailable
Income tax expense$0$0UnavailableUnavailable
Diluted EPS$-0.78$-0.02UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$157.87M$2.98MUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

Semnur Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Cash & equivalents$20.00K$12.00K$204.46K$819.75K
Total assets$1.35M$6.68M$50.69M$86.28M
Current assets$596.00K$6.00M$209.44K$907.84K
Total liabilities$22.10M$49.47M$8.49M$4.18M
Current liabilities$10.17M$35.00K$5.60M$1.29M
Total equity incl. NCI-$20.75M-$42.78M-$38.09M-$3.27M
Temporary (mezzanine) equityUnavailable$9.02M$50.48M$85.37M
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payable$5.91M$0UnavailableUnavailable

Cash flow

Semnur Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Operating cash flow-$5.87M-$4.89M-$632.78K-$426.10K
Capital expendituresUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailable$43.43M$39.71M-$84.15M
Financing cash flow$5.88M$4.89M-$39.69M$85.40M
Net change in cashUnavailableUnavailableUnavailable$819.75K
Stock-based compensation$142.44M$660.00KUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailable$43.43M$40.54MUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailable

Derived

Semnur Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable
Current ratio0.06x171.29x0.04x0.70x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SMNR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-02-27View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-15View SEC filing
10-Q · Filed 2025-05-16View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2024-12-31

Difference 9021005 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2023-12-31

Difference 29811960 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.